[Inflammation as molecular target in chondrosarcoma].
Inflammation is a hallmark in the development and progression of malignant tumors. In chondrosarcoma the inflammatory changes are relatively discrete; however, tumor-associated macrophages (TAM) may exert tumor-promoting effects. Interleukin (IL)-1 is an inflammatory cytokine which is produced by TAMs and which leads to the expression of NF-κB-regulated genes in chondrosarcoma cells, such as vascular endothelial growth factor A (VEGF-A). Through IL-1 antagonists and substances, such as curcumin IL-1-induced VEGF-A expression and angiogenesis can be blocked; therefore, IL-1-blockade provides an interesting therapy target for chondrosarcoma.
Institut für Pathologie, Otto-von-Guericke-Universität, Leipziger Str. 44, 39120, Magdeburg, Deutschland, kalinski@med.ovgu.de.
T
T
Kalinski
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology*; D002813:Chondrosarcoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000235:genetics; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
D000970:Antineoplastic Agents; D007375:Interleukin-1; D016328:NF-kappa B; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A